2seventy bio Stock News

2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Morgan Shields – Corporate Communications Chip Baird – Chief Executive Officer Vicki Eatwell – Chief Financial Officer Conference Call Participants Samantha Semenkow – Citi Daina Graybosch – Leerink Partners Operator Good day and thank you for standing by. Welcome to the 2seventy...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter ended September 30, 2024. “We are very pleased to report 42% sequential growth in quarterly Abecma sales, which was part of a continued expansion of the CAR-T class into earlier lines for multiple myeloma. When combined with the significant progress ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventy...

2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple mye...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. A live webcast of the fireside chat will be available via the Investors and Media section of the company's website a...

2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs William Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmannn - Chief Medical Officer Conference Call Participants Daina Graybosch - Leerink Kelsey Goodwin - Guggenheim Securities Operato...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the second quarter ended June 30, 2024. “This year has been transformative for 2seventy, and we enter the second half in a strong financial and operational position, poised for commercial growth,” said Chip Baird, CEO. “We dramatically reduced our cost structure and s...